MX377663B - Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados. - Google Patents

Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.

Info

Publication number
MX377663B
MX377663B MX2018009794A MX2018009794A MX377663B MX 377663 B MX377663 B MX 377663B MX 2018009794 A MX2018009794 A MX 2018009794A MX 2018009794 A MX2018009794 A MX 2018009794A MX 377663 B MX377663 B MX 377663B
Authority
MX
Mexico
Prior art keywords
synthesis
eribulin
intermediaries
methods
synthesis methods
Prior art date
Application number
MX2018009794A
Other languages
English (en)
Spanish (es)
Other versions
MX2018009794A (es
Inventor
Charles E Chase
Francis G Fang
Phil S Baran
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of MX2018009794A publication Critical patent/MX2018009794A/es
Publication of MX377663B publication Critical patent/MX377663B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Photolithography (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2018009794A 2016-02-12 2017-02-10 Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados. MX377663B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662294538P 2016-02-12 2016-02-12
PCT/US2017/017501 WO2017139664A1 (en) 2016-02-12 2017-02-10 Intermediates in the synthesis of eribulin and related methods of synthesis

Publications (2)

Publication Number Publication Date
MX2018009794A MX2018009794A (es) 2018-12-17
MX377663B true MX377663B (es) 2025-03-11

Family

ID=59563582

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018009794A MX377663B (es) 2016-02-12 2017-02-10 Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.

Country Status (10)

Country Link
US (1) US10676481B2 (enExample)
EP (1) EP3413887B1 (enExample)
JP (1) JP6786610B2 (enExample)
KR (1) KR20180107243A (enExample)
CN (1) CN108601760A (enExample)
IL (1) IL260717B (enExample)
MX (1) MX377663B (enExample)
RU (1) RU2732575C2 (enExample)
SG (1) SG11201806133UA (enExample)
WO (1) WO2017139664A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
RU2489437C2 (ru) 2007-10-03 2013-08-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Промежуточные соединения и способы синтеза аналогов галихондрина в
JP5800834B2 (ja) 2010-01-26 2015-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンb類似体の合成において有用なフロ[3,2−b]ピラン誘導体
CN114716453A (zh) 2013-11-04 2022-07-08 卫材R&D管理有限公司 软海绵素b的类似物合成中有用的大环化反应和中间体
JP6443812B2 (ja) 2013-12-06 2018-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンb類縁体の合成に有用な方法
WO2016179607A1 (en) 2015-05-07 2016-11-10 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
MX390072B (es) 2016-06-30 2025-03-20 Eisai R&D Man Co Ltd Reaccion de prins e intermediarios utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
CN111868044B (zh) 2018-01-03 2024-07-19 卫材R&D管理有限公司 可用于合成软海绵素大环内酯及其类似物的普林斯反应和化合物
CN110568121A (zh) * 2019-07-11 2019-12-13 山东省药学科学院 一种艾日布林及含艾日布林的制剂中有关物质的检测方法
KR102377262B1 (ko) * 2020-05-11 2022-03-22 연성정밀화학(주) 결정성 에리불린 염

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU652180A1 (ru) 1975-12-16 1979-03-15 Краснодарский политехнический институт 1(Фурил-2,)-2-(2-,, формилфурил-5,, ) этилен или его метильное производное как промежуточный продукт дл синтеза фуран-2,5-дикарбоновой кислоты и способ его получени
US5338865A (en) 1992-03-12 1994-08-16 President And Fellows Of Harvard College Synthesis of halichondrin B and norhalichondrin B
US5436238A (en) 1992-03-12 1995-07-25 President And Fellows Of Harvard College Halichondrins and related compounds
GB9206244D0 (en) 1992-03-23 1992-05-06 Pharma Mar Sa Cytotoxic compound from a marine sponge
TW255880B (enExample) 1992-09-09 1995-09-01 Hoechst Ag
US6194586B1 (en) 1996-09-06 2001-02-27 Eli Lilly And Company Selective sulphonation of the primary alcohol of a diol containing both primary and secondary alcohols
US6870058B2 (en) 1996-12-03 2005-03-22 The Trustees Of The University Of Pennsylvania Compounds which mimic the chemical and biological properties of discodermolide
US6653341B1 (en) 1998-06-17 2003-11-25 Eisai Co., Ltd. Methods and compositions for use in treating cancer
CN1216051C (zh) * 1998-06-17 2005-08-24 卫材株式会社 大环类似物及其使用和制备的方法
US8097648B2 (en) 1998-06-17 2012-01-17 Eisai R&D Management Co., Ltd. Methods and compositions for use in treating cancer
DE10106647A1 (de) 2001-02-12 2002-08-22 Univ Hannover Ratjadon-Derivate zum Hemmen des Zellwachstums
EP2522663B1 (en) 2004-06-03 2015-04-01 Eisai R&D Management Co., Ltd. Intermediates for the preparation of halichondrin B
US20060045846A1 (en) 2004-08-30 2006-03-02 Horstmann Thomas E Reagents and methods for labeling terminal olefins
EP1831697A4 (en) 2004-12-09 2011-01-26 Eisai R&D Man Co Ltd SCREENING OF TUBULIN ISOTYPE IN CANCER THERAPY USING ANALOGUES OF HALICHONDRIN B
US7915457B2 (en) 2005-09-26 2011-03-29 Symrise Gmbh & Co. Kg Intramolecular Prins reaction and catalysts suitable therefor
WO2008010776A1 (en) 2006-07-21 2008-01-24 Agency For Science, Technology And Research Aigialomycin d and derivatives thereof and their use in treating cancer or malaria or a microbial infection
JPWO2009014105A1 (ja) 2007-07-20 2010-10-07 株式会社山田養蜂場本社 新規カルボン酸およびそれを有効成分とする抗うつ用組成物
RU2489437C2 (ru) 2007-10-03 2013-08-10 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Промежуточные соединения и способы синтеза аналогов галихондрина в
CA2705383A1 (en) 2007-11-16 2009-05-22 Eisai R&D Management Co., Ltd. Novel intermediate for halichondrin b analog synthesis and novel desulfonylation reaction used for the intermediate
US8598373B2 (en) 2008-04-04 2013-12-03 Eisai R&D Management Co., Ltd. Halichondrin B analogs
JP5371091B2 (ja) 2009-01-23 2013-12-18 三菱レイヨン株式会社 モノスルホン酸エステルの製造方法
JP5800834B2 (ja) 2010-01-26 2015-10-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンb類似体の合成において有用なフロ[3,2−b]ピラン誘導体
WO2012147900A1 (en) * 2011-04-28 2012-11-01 Eisai R&D Management Co., Ltd. Microreactor process for halichondrin b analog synthesis
EP2785687B1 (en) 2011-11-30 2019-02-20 Sandoz AG Process for preparation of (3r)-2,4-di-leaving group-3-methylbut-1-ene
EP2831082B1 (en) 2012-03-30 2019-02-20 Sandoz AG Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein
CA2916537C (en) 2013-07-03 2021-07-27 Alphora Research Inc. Synthetic process for preparation of macrocyclic c1-keto analogs of halichondrin b and intermediates useful therein including intermediates containing -so2-(p-tolyl) groups
CN114716453A (zh) 2013-11-04 2022-07-08 卫材R&D管理有限公司 软海绵素b的类似物合成中有用的大环化反应和中间体
JP6443812B2 (ja) 2013-12-06 2018-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 ハリコンドリンb類縁体の合成に有用な方法
US10208058B2 (en) 2014-09-09 2019-02-19 Cipla Limited Process for the preparation of macrocyclic ketone analogs of halichondrin B or pharmaceutically acceptable salts and intermediates thereof
WO2016179607A1 (en) 2015-05-07 2016-11-10 Eisai R&D Management Co., Ltd. Macrocyclization reactions and intermediates and other fragments useful in the synthesis of halichondrin macrolides
MX390072B (es) 2016-06-30 2025-03-20 Eisai R&D Man Co Ltd Reaccion de prins e intermediarios utiles en la sintesis de macrolidos de halicondrina y analogos de los mismos.
WO2018217894A1 (en) 2017-05-24 2018-11-29 Eisai R&D Management Co., Ltd. Fluorine-labelled halichondrin derivatives and related methods of synthesis
CN111868044B (zh) 2018-01-03 2024-07-19 卫材R&D管理有限公司 可用于合成软海绵素大环内酯及其类似物的普林斯反应和化合物

Also Published As

Publication number Publication date
CN108601760A (zh) 2018-09-28
KR20180107243A (ko) 2018-10-01
EP3413887A1 (en) 2018-12-19
EP3413887A4 (en) 2019-08-14
US10676481B2 (en) 2020-06-09
JP2019504839A (ja) 2019-02-21
JP6786610B2 (ja) 2020-11-18
RU2732575C2 (ru) 2020-09-21
SG11201806133UA (en) 2018-08-30
US20190300542A1 (en) 2019-10-03
EP3413887B1 (en) 2021-04-07
RU2018132264A (ru) 2020-03-12
IL260717B (en) 2020-10-29
WO2017139664A8 (en) 2018-07-26
WO2017139664A1 (en) 2017-08-17
RU2018132264A3 (enExample) 2020-04-15
MX2018009794A (es) 2018-12-17

Similar Documents

Publication Publication Date Title
MX377663B (es) Intermediarios en la sintesis de eribulina y metodos de sintesis relacionados.
CY1124131T1 (el) Συζευγματα αντι-ρτκ7 αντισωματος-φαρμακου
MX2020009461A (es) Anticuerpos anti-proteína que contiene dominio de inmunologlubina rfig elacionado con el receptor de poliovirus (pvrig) y métodos de uso.
JOP20190194A1 (ar) مركبات نيوكليوتيدات ثنائية حلقية لعلاج السرطان
CL2017000545A1 (es) Anticuerpos anti-her2 e inmunoconjugados
TWD180147S (zh) 淨水器
MX387587B (es) Formulaciones subcutáneas de anticuerpos anti-cd38 y sus usos.
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
TR2021016542A2 (tr) Plazma bazlı filmler ve bunları üretme ve kullanma usulleri.
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
MX2021008376A (es) Cultivo, produccion, procesamiento y uso de cannabis de especialidad.
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX375524B (es) Anticuerpos anti-axl.
JO3791B1 (ar) تركيبات و طرق الأجسام المضادة المستهدفة لـ bmp6
UY36499A (es) Uso de picolinamidas como fungicidas
TWD182434S (zh) 修枝剪刀(一)
MX2016009590A (es) Composiciones de apilimod y métodos para usar las mismas.
MX385473B (es) Sintesis comercialmente viable de cantaridina y derivados bioactivos de cantaridina.
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
TWD187227S (zh) 淨水器
IN2015CH01182A (enExample)
PH12016501201A1 (en) Synthesis of ent-progesterone and intermediates thereof
MX374286B (es) Compuestos organolepticos novedosos.
CL2017000645A1 (es) Síntesis de ent-progesterona e intermediarios de la misma
ECSP18050673A (es) Formulaciones de giberelina en solución concentrada

Legal Events

Date Code Title Description
FG Grant or registration